Navigation Links
VIB&CD3 enter into license and collaboration agreement with AstraZeneca for development of MALT1 inhibitor

Leuven/Gent (Belgium), 31 January 2014 VIB and CD3 (KU Leuven) today announced the signing of a license and collaboration agreement with AstraZeneca for the development of novel MALT1 inhibitors as therapeutics in inflammatory and oncological diseases.

The research teams of Thijs Baens and Peter Marynen (VIB-KU Leuven, Center for Human Genetics) and Rudi Beyaert (VIB-UGent, Inflammation Research Center) were among the first to identify MALT1, an important regulator of the NF-κB signaling pathway and demonstrate its proteolytic activity on some key substrates. Since then, the proteolytic activity of MALT1 has emerged as a promising target for treatment of auto-immune disorders and certain types of cancer. VIB and CD3 launched a joint early drug discovery collaboration to identify small molecule MALT1 protease inhibitors, which now results in a license to AstraZeneca.

AstraZeneca aims to further develop the small molecule MALT1 inhibitors and, as part of the deal, the parties will join forces in an R&D collaboration to further investigate this interesting target. Both teams will undertake work outlined in the joint research plan .

Under the terms of the agreement, AstraZeneca will make an upfront payment and milestone payments based upon the achievement of development and regulatory goals. VIB and CD3 (KU Leuven) are eligible to receive royalty payments on future products developed under the agreement.

Johan Cardoen, Managing Director of VIB commented "We are very pleased with this license deal and strategic collaboration, bringing together top biological research, industry-standard early drug development and, now, a top notch industrial partner like AstraZeneca to give the program the best possible chances of success. This deal illustrates the potential of translating excellence-driven biological research into actual therapies for patients in need."

"It is great to see that the combination of the important academic research of VIB with the strengths and capabilities of CD3 has been fruitful and resulted in this license and collaboration with AstraZeneca", said Patrick Chaltin, Managing Director of CD3 at KU Leuven. "This agreement again emphasizes the strength and value of CD3's model as an investment fund and technology transfer platform for innovative drug discovery."

"This collaboration is a further example of our ambition to increase innovation by bringing together the best of academia and AZ science. We are confident that these joint efforts will increase our understanding of MALT1 and its role in autoimmunity and oncology, with the aim of discovering and developing more effective patient treatments", says Maarten Kraan, Vice President, Respiratory, Inflammation & Autoimmunity Innovative Medicines and Early Development unit, AstraZeneca Mlndal.


Contact: Kris Van der Beken
VIB (the Flanders Institute for Biotechnology)

Related biology news :

1. UK establishes 3 new synthetic biology research centers
2. £3m drug safety center investment
3. FAK helps tumor cells enter the bloodstream
4. Museum bird DNA ready for use in Naturalis Biodiversity Center
5. Eurofins and Orion Diagnostica Oy enter into an agreement on Orions proprietary SIBA technology
6. Uganda Heart Institute physicians and nurses visit Texas Childrens Heart Center
7. Army renews bio-inspired engineering and science research center at UC Santa Barbara with $48 million
8. Data centers can be cooled down in environmentally friendly, energy efficient ways
9. DFG establishes 9 new collaborative research centers
10. Wilson Center awarded European Union grant for synthetic biology work
11. Wake Forest Baptist Medical Center and Cornerstone Health Care Join in Unique Affiliation
Post Your Comments:
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
(Date:10/27/2015)... Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ... so that they can be quantitatively analyzed with SMI,s ... Germany , October 28-29, 2015. SMI,s Automated Semantic ... eye tracking videos created with SMI,s Eye Tracking ...
(Date:10/26/2015)... Oct. 26, 2015  Delta ID Inc., a company ... mobile and PC devices, announced its ActiveIRIS® technology powers ... NX F-02H launched by NTT DOCOMO, INC in ... the second smartphone to include iris recognition technology, after ... NX F-04G in May 2015, world,s first smartphone to ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
Breaking Biology Technology: